How cost-effectiveness analysis helped strengthen Bangladesh’s resolve to combat rotavirus

How cost-effectiveness analysis helped strengthen Bangladesh’s resolve to combat rotavirus hrandall Wed, 06/14/2017 – 15:56 Jun 14, 2017 Umesh Parashar Head of the Viral Gastroenteritis team in the Division of Viral Diseases, US Centers for Disease Control and Prevention (CDC) In the lead-up to Bangladesh’s introduction of rotavirus vaccines, a recently published cost-effectiveness analysis helps bolster the evidence base for decision-makers.   Bangladesh has long played a leading role in building the evidence base for interventions to combat diarrheal disease. This includes early groundbreaking research on oral rehydration solution as well as a pivotal RotaTeq® rotavirus vaccine effectiveness trial that contributed to the 2009 World Health Organization (WHO) recommendation for global rotavirus vaccination. Researchers in Bangladesh also recently completed an effectiveness trial of Rotarix® in Bangladesh to round out the evidence. So it is no surprise that Bangladesh is once again taking a leading role in its upcoming introduction of rotavirus vaccines

View this article:  

How cost-effectiveness analysis helped strengthen Bangladesh’s resolve to combat rotavirus